Ocular Therapeutix is a biopharmaceutical company developing and selling eye medications based on bioresorbable hydrogel technology. The company's marketed product, DEXTENZA, is a dexamethasone insert used to reduce inflammation and pain after eye surgery and to treat allergic conjunctivitis. Its pipeline includes AXPAXLI, currently in phase 3 trials for wet age-related macular degeneration and diabetic retinopathy, and OTX-TIC, which completed phase 2 testing for glaucoma and high eye pressure.

entry readiness 12 · NOT READY · exit proximity 0

Value area 8.16–10.08 · 29% of 120d volume overhead · moderate overhead